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Abstract
Objectives: To determine whether Irish Travellers are
over-represented amongst transfers from prison to
psychiatric hospital. If so, to determine whether this
represents an excess over the proportion of Irish
Travellers committed to prison. 
Method: Irish Travellers admitted to the National
Forensic Psychiatry service were identified from a case
register over three years 1997-1999. New prison
committals were sampled and interviewed as part of the
routine committal screening to identify ethnicity.
Results: Irish Travellers accounted for 3.4% of forensic
psychiatric admissions compared to 0.38% of the adult
population. Travellers transferred from prison to
psychiatric hospital had more learning disability and less
severe mental illness than other groups, while black and
other ethnic minorities had a higher proportion of severe
mental illness. Travellers accounted for 6% (95% CI 3-11)
of 154 male committals and 4% (95% CI 2-12) of 70
female committals. The estimated annualised prison
committal rate was 2.8% (95% CI 2.4-3.3) of all adult male
Travellers in Ireland and 1% for female Travellers (95% CI
0.8-1.3). Male Travellers had a relative risk of
imprisonment compared to the settled community of 17.4
(95% CI 2.3-131.4), the relative risk for female Travellers
was 12.9 (95% CI 1.7-96.7). Imprisoned Travellers had
greater rates of drugs and alcohol problems than other
prisoners (Relative risk 1.46, 95% CI 1.11-1.90).
Conclusion: There is gross over-representation of
Travellers in forensic psychiatric admissions. This reflects
the excess of Travellers amongst prison committals. 
Key words: Irish Travellers; Ethnic minorities; Prison;
Forensic Psychiatry; Drugs; Alcohol.
Black and minority ethnic groups are commonly over-repre-
sented amongst those formally detained under mental health
legislation, and this is most pronounced in secure forensic
institutions.1,2 Research has shown differential representation
of ethnic subgroups in the criminal justice process. Black
adult males in the UK of African and Caribbean origin were
imprisoned at 6.7 times the age-adjusted rate of white males
in 1991.3 African American men are estimated to be impris-
oned at a rate six times that of white men.4
Travellers are a small indigenous ethnic minority, docu-
mented as being part of Irish society for centuries. They have
a long shared history and value system, which make them a
distinct group. They have their own language, customs and
traditions. The distinctive Traveller lifestyle and culture based
on a nomadic tradition sets Travellers apart from the seden-
tary population or ‘settled people’.5 
Travellers are widely acknowledged as one of the most
marginalised and disadvantaged groups in Irish society. Trav-
ellers fare poorly on every indicator used to measure
disadvantage: unemployment; poverty; social exclusion;
health status; infant mortality; life expectancy; accommoda-
tion and living conditions.6,7
In Ireland, Travellers are recognised as a distinct group for
census purposes and Pavee Point supported the proposal to
include an ethnic question for all in the 2002 census.8
The processes of stigmatisation and institutional disad-
vantage are of particular importance in psychiatry. Stigma can
arise from and also contribute to mental disorders, leading to
disadvantages in housing, employment and direct or indirect
criminalisation.9 Even those with non-psychiatric disorders
such as epilepsy can find themselves over-represented in the
criminal justice system if their illness is sufficiently stigmatis-
ing.10 The opportunity to study processes of criminalisation in
a discrete ethnic group who are not distinguished in the usual
ways by colour or nationality is therefore instructive.
We hypothesised that if there is an excess of travellers
admitted to the Central Mental Hospital, it is a passive reflec-
tion of the proportion of travellers committed to the Irish
prison system.
Method
There are about 4,790 Traveller families or an estimated
21,158 Travellers in Ireland based on figures compiled by the
Department of Environment and local housing authorities.11,12
This is an annual count of Traveller families in:
• Local authority or local authority assisted accommodation
• On the roadside 
• Other private accommodation. 
This figure is a more accurate estimate of the Traveller
population than the 1996 population census figures,
because it includes settled Travellers. The 1996 census
showed that the Traveller community has a markedly different
age and sex structure from that of the population in general.12
Within the Traveller population 50% were aged under 15
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years, only 1.3% were over 65, and 49% were male. Trav-
ellers account for about 0.38% of the adult population. From
these figures we calculate that there are 10,441 Travellers
aged 15-65. There were 2,352,781 adults aged 15-65 in the
total Irish population at the 1996 census.
A computerised case register of all admissions to the
Central Mental Hospital for the three years 1997-1999 was
compiled from a written register and cross-checked with
ward admission records. During the study period, all trans-
fers from the prisons to mental hospital in the State were to
the Central Mental Hospital. There were 476 admissions of
352 individuals during the three-year period. Ethnicity was
elicited from records and corroborated by consultation with
staff to minimise the risk of under-estimation of Traveller
numbers. Patients were classified as white European (to
include European Union nationals but excluding Irish Trav-
ellers, thereby encompassing those not stigmatised by colour
or ethnicity), black and other minority ethnic groups (to coin-
cide with stigmatised groups) and Irish Travellers. 
Discharge diagnosis was recorded for each patient
according to the ICD-10 multi-axial system based on the
multi-disciplinary team assessment and information from inde-
pendent informants. No formal research instrument was in
use.
The study of prison committals was carried out at Cloverhill
Prison, the largest remand prison for the country, and the
Dochas Centre Mountjoy Prison, the largest women’s prison.
All new committals were interviewed as part of the routine
health screening of all individuals received at the prison, by a
nurse and also by a researcher who was a post-membership
psychiatrist. Ethnicity was elicited by self-definition. A history
of drugs and alcohol problems was elicited by direct ques-
tioning for clinical purposes, to elicit those likely to require
detoxification. As a check on the reliability of these self-
reports, routine urine checks showed that of 86 reporting an
opiate problem who had urine checks, 79 (92%) were posi-
tive. Those who did not have urine checks were previously
known to the prison staff. Self-report on committal appears
to be reliable for opiates and is likely to be reliable for alcohol
and other substances.
There were 352 new committals to Cloverhill prison over
the four weeks from October 9-November 5, 2000. New
committals to Cloverhill Prison (154 male remands) were
screened jointly by a researcher and a nurse employed by the
prison service over this period. On 21 sampling days, chosen
to be equivalent to three weeks continuous sampling, all new
committals were jointly screened. None of those screened
were committed twice during the study period. Similarly there
were 146 new female committals during the six-week
sampling period between October 2 and November 12,
2000. None was committed twice during the study period.
On 21 days chosen to be equivalent to three weeks continu-
ous sampling, 70 women were jointly screened.
Results
Admissions to the Central Mental Hospital
There were 28 admissions of Travellers, or 4.7% of the
total 476 in the three years 1997-1999. Over the same
period, there were 12 admissions (2.5% of total) of individu-
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White European Black & ethnic minorities Travellers Total
No. No. No.
%(95% CI) %(95% CI) %(95% CI)
Minor mental illness 92 2 8 102
% of total within 20.7(17.2 to 24.7) 16.7(4.7-44.8) 28.6(15.3-47.1)
ethnicity and 95% CI
Severe mental illness 184. 10 6 200
41.4(37.0-46.1) 83.3(55.2-95.3) 21.4(10.2-29.5)
Personality disorder or 112 0 7 119
paraphilia 25.2(21.4-39.5) 0(0-24.3) 25.0(12.7-43.4)
Learning disability 15 0 6 21
3.4 (2.1-5.5) 0(0-24.3) 21.4(10.2-39.5)
Substance abuse 41 0 1 42
9.2(6.9-12.3) 0(0-24.3) 3.6(0.6-17.7)
Total 444 12 28 484
Table 1: Diagnosis and ethnicity for all admissions to the CMH, 1997-1999
Ethnic group Males Females Total
No No No
%(95%CI) %(95%CI) %(95%CI)
White European 142 58 200  
excl. Travellers 92%(87%-96%) 83%(72%-90%) 89%(85%-93%)
Black and other 3 9 12
minority ethnic 2%(1%-6%) 13%(7%-23%) 5%(3%-9%)
groups
Travellers 9 3 12
6%(3%-11%) 4%(2%-12%) 5%(3%-9%)
Totals 154 70 224
Table 2: Committal screening sample from Clover Hill Prison (males) 
and the Dochas centre, Mountjoy (females)
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als from black or other minority ethnic groups,
including those from European countries outside
the European Union. Taking the most conservative
estimate by excluding re-admissions, these repre-
sent 12 individual Travellers out of 352 individuals
admitted or 3.4% of individuals admitted over the
three years 1997-1999 (95% CI 2.0-5.9). Simi-
larly, the 12 admissions of black patients
represent 10 individuals out of the 352 people
admitted (2.8%, 95% CI 1.6-5.1). White Euro-
peans (ie. white Irish and other EU nationals, who
would not be expected to incur any stigma due to
race or ethnicity), accounted for 330 of the 352
individuals admitted (93.8%, 95% CI 90.7-95.8).
Travellers compared to other admissions to the
Central Mental Hospital had less severe mental
illness than white Europeans, and more learning
disability. Black and other ethnic minorities had a
marked excess of severe mental illness when
compared with other groups (see Table 1).
When the gravity of the offence for which the
patient was imprisoned was compared across
ethnic groups, no significant differences emerged.
Prison committals
Travellers accounted for 6% (95% CI 3-11) of
male prison committals and 4% (95% CI 2-12) of
female committals (see Table 2). The annualised
committal rate for male Travellers was 2.8% (95%
CI 2.4-3.3) of all adult male Travellers in Ireland
and 1% for adult female Travellers (95% CI 0.8-
1.3). Male Travellers had a relative risk of
imprisonment compared to the settled community
of 17.4 (95% CI 2.3-131.4), 12.9 for female Trav-
ellers (95% CI 1.7-96.7) (see Table 3). 
Comparing remanded male Travellers with
remanded white Europeans (ie. from within the
EU), for self-reported drugs and alcohol problems
combined (see Table 4), imprisoned Travellers are
significantly more likely to report problems with
drugs and alcohol (relative risk 1.46, 95% CI
1.11-1.9). 
Discussion
The ethnicity of all new committals to Cloverhill
Prison was elicited by self-definition in this study.
The ethnicity of admissions to the Central Mental
Hospital was ascertained retrospectively, by
review of medical records and staff appraisal. It is
possible that the number of Travellers admitted to
the Central Mental Hospital was an underesti-
mate of the true rate of admissions. The task force
report on the Travelling community recommended
that all health data systems should include a
question on ethnic group. This would facilitate
data collection and proper health planning for all
ethnic minorities, including Travellers.
The prison sample was equivalent to three
weeks continuous sampling. This represents only
a small proportion of committals to Cloverhill
Prison annually. A further longitudinal study of
committals is warranted to confirm our initial find-
ing of the over-representation of Travellers among
committals to remand centres.
Detection of psychiatric illness may have been
hampered by the lack of a standardised screen-
ing tool for diagnosis of illness. The environment
in which screening took place in the prison did
not afford privacy and confidentiality to prisoners.
This may have resulted in inadequate disclosure
of illness to the researchers. We have therefore
only reported the discharge diagnosis for those
admitted to the Central Mental Hospital.
Our study confirms our original hypotheses that
Irish Travellers, as an ethnic group, represent a
disproportionate number of those admitted to the
Central Mental Hospital and that both male and
female Travellers have significantly higher prison
committal rates than the general population. This
over-representation might be an artefact if the
number of Travellers in the adult population is
substantially underestimated, but this would
require approximately 95% of Travellers to have
been missed in population estimates, and Trav-
ellers would have to account for almost 7% of the
adult population. Our findings are similar to stud-
ies of ethnic minorities in other jurisdictions and
highlight the differential representation of minor-
ity ethnic groups in the criminal justice process.
Although Travellers and other ethnic minorities
are significantly over-represented in the admis-
sions to the Central Mental Hospital, these
hospital admissions are merely following the
pattern of over-representation amongst prison
committals. The extremely high imprisonment rate
for the Traveller community as a whole should be
confirmed in a larger study. These rates suggest
that a very high proportion of all Travellers will be
imprisoned at some time during their life. This
‘normalisation’ of the experience of imprisonment
exposes a high proportion of all Travellers to the
adverse health and lifestyle behaviours prevalent
in prisons. Prison populations are at great risk of
developing opiate and other drug dependence
disorders, with associated problems.13 In a more
per 100,000 adults Male rate Female rate  Relative risk  
per annum Males v Females
No No No
(95% CI) (95% CI) (95% CI)
General population 186 83 2.22
(179-193) (78-88) (0.9-5.4)
Travellers 2800 1000 2.9
(2400-3300) (800-1300) (0.8-10.6)
Relative risk travellers 17.4 12.9
v general population (2.3-131.4) (1.7-96.7)
(95% CI)
Table 3: Annualised committal rate per 100,000 for adults (> 15 years)
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general way, the normalisation of imprisonment is likely to
have adverse effects on the expectations and aspirations of
children and adults. It adds also to the stigma attached to
Travellers as a group.
Heron et al report that Traveller women have high levels of
psychological distress, higher in those with the worst accom-
modation and environmental facilities.14 Travellers admitted to
the Central Mental Hospital had less severe mental illness
than white Europeans, and more learning disability. This
distinguishes them from other ethnic minorities in the same
series who showed a marked excess of severe mental illness
when compared with white Europeans.
Imprisoned Travellers are significantly more likely to report
problems with drugs and alcohol. Self-report is a soft
measure, but it is a reflection of willingness to accept treat-
ment. This does not prove that all Travellers as a group have
a higher prevalence of drugs and alcohol problems, but it
suggests that they may be more likely than the settled popu-
lation to be imprisoned if they have a drugs or alcohol
problem. This may reflect the difficulties Travellers experience
in accessing drug and alcohol services. 
Travellers show a high utilisation of general practitioner and
accident and emergency services, and a low utilisation of
other hospital services including aftercare, preventive
services and specialised services such as psychiatric care.
Low levels of literacy and a nomadic lifestyle have been iden-
tified as barriers to Travellers gaining access to the health
services. 
Prejudice on the part of the general public and service
providers may also result in Travellers being refused access
to health services.15 Little is known concerning the extent to
which Travellers are over or under-represented in general
adult psychiatric services. Less is known regarding the true
prevalence of mental illnesses in the Traveller population.
The systematic induction into prison of a significant propor-
tion of any identifiable group within society is a cause for
concern. From a mental health perspective, prisoners have
an increased risk of suicide.16-18 And prisoners have more
mental health problems than the general population.19 Use of
injected drugs and infection with hepatitis C and other
viruses are endemic in Irish prisons, and only a small number
of first time prison entrants were infected with one or more of
the blood-borne viruses.13 
Imprisonment disrupts work, education, marriage and
parenting in ways that are harmful to the prisoner and to the
prisoner’s family.20
In any ethnic group or sub-population where imprisonment
is so common, it is reasonable to hypothesise for future
research that the lowered life expectancy, the impaired phys-
ical and mental health, may to some extent be caused by
imprisonment itself. 
A practical consequence would be to use contact with the
criminal justice system as a means of engaging individuals in
culture-specific programmes for health promotion, examples
of which can be found in other jurisdictions. In Canada,21
Australia and New Zealand,22,23 indigenous minorities are also
over-represented in prisons and forensic psychiatric institu-
tions. Approaches to specific services24 and training25 have
been described and should be considered in the Irish mental
health services and also in the Irish courts and prison service.
Declaration of Interest: None.
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White EU Irish Travellers Relative Risk 
nationals (95% CI)
Total No. 142 9
Alcohol 34(24%) 4(44%) 1.80(0.80-4.00)
Opiates 53(37%) 4(44%) 1.18(0.55-2.53)
Substance abuse 86(43%) 8(89%) 1.46(1.11-1.90)
problems combined
Table 4: Self-reported substance abuse (males only) at reception, 
Cloverhill Prison
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